vs

Side-by-side financial comparison of FutureFuel Corp. (FF) and OptimizeRx Corp (OPRX). Click either name above to swap in a different company.

OptimizeRx Corp is the larger business by last-quarter revenue ($32.2M vs $19.8M, roughly 1.6× FutureFuel Corp.). OptimizeRx Corp runs the higher net margin — 15.6% vs -60.5%, a 76.1% gap on every dollar of revenue. On growth, OptimizeRx Corp posted the faster year-over-year revenue change (-0.2% vs -67.7%). OptimizeRx Corp produced more free cash flow last quarter ($7.1M vs $-29.9M). Over the past eight quarters, OptimizeRx Corp's revenue compounded faster (28.0% CAGR vs -41.7%).

FutureFuel Corporation is a developer and producer of chemicals and biofuels. It is listed on the New York Stock Exchange, with symbol FF.

OptimizeRx Corp is a U.S.-headquartered digital health technology company that delivers patient engagement, medication affordability and clinical communication solutions to life sciences enterprises, healthcare providers and pharmacy partners. Its core offerings include digital medication savings tools, patient support programs, and therapeutic area-specific resources to boost medication access and treatment adherence.

FF vs OPRX — Head-to-Head

Bigger by revenue
OPRX
OPRX
1.6× larger
OPRX
$32.2M
$19.8M
FF
Growing faster (revenue YoY)
OPRX
OPRX
+67.5% gap
OPRX
-0.2%
-67.7%
FF
Higher net margin
OPRX
OPRX
76.1% more per $
OPRX
15.6%
-60.5%
FF
More free cash flow
OPRX
OPRX
$36.9M more FCF
OPRX
$7.1M
$-29.9M
FF
Faster 2-yr revenue CAGR
OPRX
OPRX
Annualised
OPRX
28.0%
-41.7%
FF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FF
FF
OPRX
OPRX
Revenue
$19.8M
$32.2M
Net Profit
$-12.0M
$5.0M
Gross Margin
-46.7%
74.8%
Operating Margin
-62.9%
26.6%
Net Margin
-60.5%
15.6%
Revenue YoY
-67.7%
-0.2%
Net Profit YoY
-529.4%
6535.9%
EPS (diluted)
$-0.28
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FF
FF
OPRX
OPRX
Q4 25
$19.8M
$32.2M
Q3 25
$22.7M
$26.1M
Q2 25
$35.7M
$29.2M
Q1 25
$17.5M
$21.9M
Q4 24
$61.5M
$32.3M
Q3 24
$51.1M
$21.3M
Q2 24
$72.4M
$18.8M
Q1 24
$58.3M
$19.7M
Net Profit
FF
FF
OPRX
OPRX
Q4 25
$-12.0M
$5.0M
Q3 25
$-9.3M
$779.0K
Q2 25
$-10.4M
$1.5M
Q1 25
$-17.6M
$-2.2M
Q4 24
$2.8M
$-78.0K
Q3 24
$-1.2M
$-9.1M
Q2 24
$9.6M
$-4.0M
Q1 24
$4.3M
$-6.9M
Gross Margin
FF
FF
OPRX
OPRX
Q4 25
-46.7%
74.8%
Q3 25
-30.1%
67.2%
Q2 25
-24.6%
63.8%
Q1 25
-83.0%
60.9%
Q4 24
9.1%
68.1%
Q3 24
0.7%
63.1%
Q2 24
12.0%
62.2%
Q1 24
8.6%
62.0%
Operating Margin
FF
FF
OPRX
OPRX
Q4 25
-62.9%
26.6%
Q3 25
-42.9%
7.9%
Q2 25
-33.4%
10.9%
Q1 25
-107.4%
-9.6%
Q4 24
2.6%
11.2%
Q3 24
-5.6%
-40.2%
Q2 24
7.5%
-19.9%
Q1 24
3.8%
-25.5%
Net Margin
FF
FF
OPRX
OPRX
Q4 25
-60.5%
15.6%
Q3 25
-41.1%
3.0%
Q2 25
-29.2%
5.2%
Q1 25
-100.6%
-10.0%
Q4 24
4.5%
-0.2%
Q3 24
-2.3%
-42.8%
Q2 24
13.2%
-21.3%
Q1 24
7.4%
-35.0%
EPS (diluted)
FF
FF
OPRX
OPRX
Q4 25
$-0.28
$0.27
Q3 25
$-0.21
$0.04
Q2 25
$-0.24
$0.08
Q1 25
$-0.40
$-0.12
Q4 24
$0.06
$0.00
Q3 24
$-0.03
$-0.50
Q2 24
$0.22
$-0.22
Q1 24
$0.10
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FF
FF
OPRX
OPRX
Cash + ST InvestmentsLiquidity on hand
$51.3M
$23.4M
Total DebtLower is stronger
$26.3M
Stockholders' EquityBook value
$154.7M
$128.3M
Total Assets
$192.2M
$176.9M
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FF
FF
OPRX
OPRX
Q4 25
$51.3M
$23.4M
Q3 25
$85.6M
$19.5M
Q2 25
$95.2M
$16.6M
Q1 25
$97.1M
$16.6M
Q4 24
$109.5M
$13.4M
Q3 24
$133.4M
$16.1M
Q2 24
$115.1M
Q1 24
$201.1M
Total Debt
FF
FF
OPRX
OPRX
Q4 25
$26.3M
Q3 25
$28.8M
Q2 25
$29.3M
Q1 25
$33.8M
Q4 24
$34.3M
Q3 24
$36.8M
Q2 24
$37.3M
Q1 24
$37.8M
Stockholders' Equity
FF
FF
OPRX
OPRX
Q4 25
$154.7M
$128.3M
Q3 25
$169.1M
$122.3M
Q2 25
$178.2M
$119.3M
Q1 25
$188.4M
$116.3M
Q4 24
$205.8M
$117.0M
Q3 24
$213.3M
$114.5M
Q2 24
$214.4M
$121.0M
Q1 24
$204.8M
$122.5M
Total Assets
FF
FF
OPRX
OPRX
Q4 25
$192.2M
$176.9M
Q3 25
$203.5M
$170.3M
Q2 25
$218.2M
$169.3M
Q1 25
$227.7M
$167.8M
Q4 24
$247.7M
$171.2M
Q3 24
$256.5M
$165.2M
Q2 24
$261.2M
$172.9M
Q1 24
$365.4M
$176.4M
Debt / Equity
FF
FF
OPRX
OPRX
Q4 25
0.20×
Q3 25
0.24×
Q2 25
0.25×
Q1 25
0.29×
Q4 24
0.29×
Q3 24
0.32×
Q2 24
0.31×
Q1 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FF
FF
OPRX
OPRX
Operating Cash FlowLast quarter
$-27.4M
$7.1M
Free Cash FlowOCF − Capex
$-29.9M
$7.1M
FCF MarginFCF / Revenue
-150.5%
22.0%
Capex IntensityCapex / Revenue
12.2%
0.0%
Cash ConversionOCF / Net Profit
1.41×
TTM Free Cash FlowTrailing 4 quarters
$-46.0M
$18.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FF
FF
OPRX
OPRX
Q4 25
$-27.4M
$7.1M
Q3 25
$-1.1M
$3.2M
Q2 25
$5.2M
$4.6M
Q1 25
$-5.4M
$3.9M
Q4 24
$-16.6M
$198.0K
Q3 24
$25.8M
$1.8M
Q2 24
$27.8M
$782.0K
Q1 24
$-12.2M
$2.1M
Free Cash Flow
FF
FF
OPRX
OPRX
Q4 25
$-29.9M
$7.1M
Q3 25
$-6.5M
$3.2M
Q2 25
$-263.0K
$4.6M
Q1 25
$-9.4M
$3.8M
Q4 24
$-20.7M
$181.0K
Q3 24
$20.5M
$1.8M
Q2 24
$24.8M
$737.0K
Q1 24
$-14.5M
$2.1M
FCF Margin
FF
FF
OPRX
OPRX
Q4 25
-150.5%
22.0%
Q3 25
-28.5%
12.2%
Q2 25
-0.7%
15.6%
Q1 25
-53.6%
17.5%
Q4 24
-33.6%
0.6%
Q3 24
40.1%
8.3%
Q2 24
34.3%
3.9%
Q1 24
-24.9%
10.6%
Capex Intensity
FF
FF
OPRX
OPRX
Q4 25
12.2%
0.0%
Q3 25
23.5%
0.0%
Q2 25
15.3%
0.0%
Q1 25
22.8%
0.1%
Q4 24
6.6%
0.1%
Q3 24
10.4%
0.1%
Q2 24
4.1%
0.2%
Q1 24
3.9%
0.2%
Cash Conversion
FF
FF
OPRX
OPRX
Q4 25
1.41×
Q3 25
4.11×
Q2 25
2.98×
Q1 25
Q4 24
-5.94×
Q3 24
Q2 24
2.90×
Q1 24
-2.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FF
FF

Chemicals$18.0M91%
Biofuels$1.8M9%

OPRX
OPRX

Segment breakdown not available.

Related Comparisons